Open AccessMetabolic Syndrome and the Risk of Preclinical Heart Failure: Insights after 17 Years of Follow-Up from the STANISLAS Cohort
Author(s) -
Abhinav Sharma,
Amir Razaghizad,
João Pedro Ferreira,
JeanLoup Machu,
Erwan Bozec,
Nicolas Girerd,
Patrick Rossignol,
Faı̈ez Zannad
Publication year - 2022
Publication title -
cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.547
H-Index - 63
eISSN - 1421-9751
pISSN - 0008-6312
DOI - 10.1159/000523717
Subject(s) - medicine , waist , metabolic syndrome , cohort , odds ratio , heart failure , prospective cohort study , logistic regression , demography , cardiology , obesity , sociology
BackgroundWe used data from participants initially free of clinical cardiovascular disease in the STANISLAS cohort to evaluate the association between metabolic syndrome (MS) and development of preclinical heart failure (HF).Methods and ResultsThe STANISLAS cohort is a single‐center familial longitudinal cohort composed of 1006 families from the Nancy region of France (median follow-up of 17 years [1993-2016]). Age and sex matched logistic regression models and inverse probability weighting models were used to determine the association of MS and preclinical HF. Among 944 adult patients at the final visit, those with baseline MS, compared to patients who developed MS and those without MS, were more likely to be older (63 vs 61 vs 59 years of age) and male (73% vs 55% vs 45%). The risk of preclinical HF was numerically increased, compared to patients without MS, among patients who developed MS (adjusted odds ratio [aOR] 1.56, 95% CI 1.00-2.43) and patients with MS at baseline (aOR 2.27, 95% CI 1.07-4.81). Among the individual components of MS, the risk of preclinical HF was elevated in individuals with baseline hypertension (aOR 3.19, 95% CI 1.80-5.63) and baseline elevated waist circumference (aOR 2.59, 95% CI 1.47-4.57).Conclusion Given the high risk of mortality when patients with metabolic syndrome or elevated fasting glucose become established with HF failure, HF prevention remains an important public health concern. Evaluation of early aggressive lifestyle and possibly medical intervention among patients free of cardiovascular disease with an obese-hypertensive phenotype to prevent future HF development is warranted.